CELEX: 62013CN0210
Language: en
Date: 2013-04-18 00:00:00
Title: Case C-210/13: Reference for a preliminary ruling from High Court of Justice (Chancery Division) (United Kingdom) made on 18 April 2013 — Glaxosmithline Biologicals SA, Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG v Comptroller-General of Patents, Designs and Trade Marks

29.6.2013   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 189/8
            
         Reference for a preliminary ruling from High Court of Justice (Chancery Division) (United Kingdom) made on 18 April 2013 — Glaxosmithline Biologicals SA, Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG v Comptroller-General of Patents, Designs and Trade Marks
   (Case C-210/13)
   2013/C 189/15
   Language of the case: English
   
      Referring court
   
   High Court of Justice (Chancery Division)
   
      Parties to the main proceedings
   
   
      Applicants: Glaxosmithline Biologicals SA, Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG
   
      Defendant: Comptroller-General of Patents, Designs and Trade Marks
   
      Questions referred
   
   
               1.
            
            
               Is an adjuvant which has no therapeutic effect on its own, but which enhances the therapeutic effect of an antigen when combined with that antigen in a vaccine, an ‘active ingredient’ within the meaning of Article 1(b) of Regulation 469/2009/EC (1)?
            
         
               2.
            
            
               If the answer to question 1 is no, can the combination of such an adjuvant with an antigen nevertheless be regarded as a ‘combination of active ingredients’ within the meaning of Article 1(b) of Regulation 469/2009/EC?
            
         
      (1)  Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products
   OJ L 152, p. 1